Malignant phosphaturic mesenchymal tumor with pulmonary metastasis: A case report. Issue 17 (April 2017)

• Record Type: Journal Article
• Authors: Qiu, Shui; Cao, Li-Li; Qiu, Yue; Yan, Ping; Li, Zi-xuan; Du, Jiang; Sun, Li-Mei; Zhang, Qing-Fu
• Other Names: Boros. Laszlo Geza section editor.
• Is Part Of: Medicine. Volume 96:Issue 17(2017)
• Publication Date: 2017-04
• Subjects: fibroblast growth factor 23 -- immunohistochemistry -- phosphaturic mesenchymal tumor -- tumor-induced osteomalacia; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000006750
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale: Phosphaturic mesenchymal tumor (PMT) is a new tumor entity of soft tissue and bone tumor recently accepted by the World Health Organization, which typically causes the paraneoplastic syndrome of tumor-induced osteomalacia (TIO). The majority of PMTs follow a benign clinical course and local recurrence occurs in < 10% of cases, malignant PMTs with distant organ metastasis are extremely uncommon. Patient concerns: We reported a 41-year-old woman who was diagnosed with PMT 10 years ago with a repeated recurrence and pulmonary metastasis. Diagnoses: Based on clinical manifestations, MRI scan, serum biochemical indicators evaluation, followed by histopathological examination, the patient was diagnosed as malignant PMT with pulmonary metastasis. Interventions: The patient was treated with calcium, phosphorus, and vitamin D after surgical resection and measured the serum ion concentrations every 3 months. Outcomes: The patient had a favorable outcome for 10 months without recurrence. Lessons: PMTs lack of characteristic histological morphology, some recurrence cases may appear benign morphologically; the malignant PMTs are easily overlooked. Patients with PMT should be carefully evaluated and monitored, in order to early identify its malignant potential.